Form 4: Zenas BioPharma Director Patricia L. Allen Acquires Stock Options
SEC Form 4
Patricia L. Allen, a director of Zenas BioPharma, acquired stock options for 18,500 shares on September 12, 2024.
Summary
- Patricia L. Allen, a director of Zenas BioPharma, filed a Form 4 on September 16, 2024.
- On September 12, 2024, Allen acquired options to purchase 18,500 shares of Zenas BioPharma common stock at an exercise price of $17.
- The options vest on September 12, 2025, contingent upon continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects insider trading activity, which can be interpreted in various ways but doesn't inherently indicate positive or negative sentiment.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- Shareholders may view the director's stock option acquisition as a sign of confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of transaction: Patricia L. Allen acquired stock options. |
| 09/12/2025 | Vesting date for the stock options. |
| 09/11/2034 | Expiration date for the stock options. |
| 09/16/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.